Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 399

1.

Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.

Guirguis A, Elishaev E, Oh SH, Tseng GC, Zorn K, DeLoia JA.

Gynecol Oncol. 2008 Feb;108(2):370-6.

PMID:
18083218
2.

beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.

Moreno-Bueno G, Gamallo C, Pérez-Gallego L, de Mora JC, Suárez A, Palacios J.

Diagn Mol Pathol. 2001 Jun;10(2):116-22.

PMID:
11385321
3.

Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.

Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ.

Clin Cancer Res. 2005 Sep 15;11(18):6422-30.

4.

Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.

Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J.

Clin Cancer Res. 2005 Sep 1;11(17):6300-10.

5.

[Study of differential gene expression in different stage human endometrial cancer].

Wan XP, Cai B, Liu L, Xi XW, Yang YX.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jan;41(1):38-42. Chinese.

PMID:
16635327
6.

Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.

Maxwell GL, Chandramouli GV, Dainty L, Litzi TJ, Berchuck A, Barrett JC, Risinger JI.

Clin Cancer Res. 2005 Jun 1;11(11):4056-66.

7.

Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium.

Cao QJ, Belbin T, Socci N, Balan R, Prystowsky MB, Childs G, Jones JG.

Int J Gynecol Pathol. 2004 Oct;23(4):321-9.

PMID:
15381901
8.

Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.

Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET.

J Natl Cancer Inst. 2002 Jul 3;94(13):990-1000.

PMID:
12096084
9.
10.

Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.

Shedden KA, Kshirsagar MP, Schwartz DR, Wu R, Yu H, Misek DE, Hanash S, Katabuchi H, Ellenson LH, Fearon ER, Cho KR.

Clin Cancer Res. 2005 Mar 15;11(6):2123-31.

11.

Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling.

Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS, Chan SC, Ho TW, Wong KW, Yu MY, Wang VW, Li C, Gardner GJ, Bonome T, Johnson WB, Smith DI, Chung TK, Birrer MJ.

Oncogene. 2007 Mar 22;26(13):1971-82. Epub 2006 Oct 16.

PMID:
17043662
12.

Comparison of the molecular classification with FIGO stage and histological grade on endometrial cancer.

Cai B, Liu L, Xi W, Zhu YP, Lu GZ, Yang YX, Wan XP.

Eur J Gynaecol Oncol. 2007;28(6):451-60.

PMID:
18179135
13.

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.

Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI.

Clin Cancer Res. 2005 Mar 15;11(6):2149-55.

14.

Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.

Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr, Lu KH.

Clin Cancer Res. 2005 Sep 1;11(17):6116-26.

15.

Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors.

Huvila J, Brandt A, Rojas CR, Pasanen S, Talve L, Hirsimäki P, Fey V, Kytömäki L, Saukko P, Carpén O, Soini JT, Grénman S, Auranen A.

Int J Gynecol Cancer. 2009 Oct;19(7):1226-31. doi: 10.1111/IGC.0b013e3181b33be0.

PMID:
19823059
16.

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD.

Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196.

17.

Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.

Watari H, Xiong Y, Hassan MK, Sakuragi N.

Gynecol Oncol. 2009 Jan;112(1):229-34. doi: 10.1016/j.ygyno.2008.09.039. Epub 2008 Nov 12.

PMID:
19007976
18.

A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma.

Planagumà J, Díaz-Fuertes M, Gil-Moreno A, Abal M, Monge M, García A, Baró T, Thomson TM, Xercavins J, Alameda F, Reventós J.

Cancer Res. 2004 Dec 15;64(24):8846-53.

19.

Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.

Risinger JI, Maxwell GL, Chandramouli GV, Aprelikova O, Litzi T, Umar A, Berchuck A, Barrett JC.

Cancer Res. 2005 Jun 15;65(12):5031-7.

20.

Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications.

Orlandi A, Ferlosio A, Ciucci A, Francesconi A, Lifschitz-Mercer B, Gabbiani G, Spagnoli LG, Czernobilsky B.

Mod Pathol. 2006 Jun;19(6):797-803.

Supplemental Content

Support Center